Clinical trial
Serp-1 for the Treatment of Acute Coronary Syndrome
NCT00243308 · Viron Therapeutics Inc, Industry · Terminated
Key facts
| NCT number | NCT00243308 |
|---|---|
| Title | Serp-1 for the Treatment of Acute Coronary Syndrome |
| Official title | A Phase 2, Multicentre, Double-Blind, Placebo-Controlled, Dose Escalating Trial of the Safety, Pharmacokinetics, and Biological Activity of 3 Consecutive Daily Doses of Serp-1 When Added to Conventional Therapy in Patients With Acute Coronary Syndromes (Non ST-Elevation Myocardial Infarction and/or… |
| Lead sponsor | Viron Therapeutics Inc, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Unstable Angina, Coronary Atherosclerosis, Coronary Restenosis |
| Intervention type | Drug |
| Interventions | Serine proteinase-1 (Serp-1) |
| Enrollment | 72 |
| Start date | Oct 1, 2005 |
| Primary completion | Jul 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Oct 21, 2005 |
| Last update posted | Feb 6, 2009 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: